Argus 2.0 Adoption Study (NCT07425236)
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates the usability of the KOS Argus Continuous Glucose Monitoring (CGM) System, a noninvasive, wrist-worn device that estimates blood glucose levels using light-based sensors and artificial intelligence algorithms. The Argus device does not puncture the skin or require sensor insertions. The study will enroll up to 100 adults with type 1 diabetes, type 2 diabetes, or prediabetes at a single site. Participants will complete a screening visit, followed by a Day 1 in-clinic baseline visit that includes serial venous blood draws approximately every 10 minutes over 6 hours to collect paired reference blood glucose measurements alongside Argus device readings. After the baseline visit, participants will wear the Argus device and a commercially available Dexcom Stelo CGM continuously for 15 days during normal daily activities. The primary objective is to collect paired glucose data to support device development and algorithm training. Participants will not receive glucose readings from the Argus device and will continue their usual diabetes management throughout the study. Secondary objectives include assessing device safety, tolerability, adherence, and operational lifespan over the 15-day wear period.
Who can join: Review the eligibility criteria below.
Location: Mills-Peninsula Medical Center - San Mateo Campus — San Mateo, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Mills-Peninsula Medical Center - San Mateo Campus — San Mateo, California
📞 Contact the Study Coordinator
Phone: (650) 666-9721
Email: kw@kos-ai.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes
- Northern Manhattan Study of Metabolism and Mind — New York, New York
- The Effect of Grocery Support Dose on Food Insecurity and Disease Control Among Covered California Members With Diabetes or Hypertension — San Francisco, California
- Eversense® Non-adjunctive Use Post Approval Study — Los Angeles, California
- Evaluating the Health Outcomes of the Joslin Why WAIT Program — Boston, Massachusetts
- Community Engagement Alliance Against Disparities — Washington D.C., District of Columbia
- Meta-Analyses of the Effect of Plant Protein Versus Animal Protein on Cardiometabolic Risk — Toronto, Ontario
Explore by condition: All Diabetes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.